StudyFinder
Search Results Within Category "Weight/Nutrition"
4 Study Matches
Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)
Lily Deng - lily.deng@cchmc.org
ALL
10 years and over
PHASE2
NCT07029009
Inclusion Criteria:
* Diagnosis of MODY via genetic testing
* HgbA1c \>6.5%
Exclusion Criteria:
* History of anaphylaxis to GLP-1 receptor agonists
* Already taking GLP-1 receptor agonists
* on medications within the stimulant class
* have had bariatric surgery
* personal or family history of cancer, especially medullary thyroid cancer
* personal history of pancreatitis or pathogenic variants associated with increased risk of pancreatitis
* known active kidney disease
* severe hypoglycemia (glucose \< 50 mg/dL) within 3 months of study enrollment
* HbA1c \> 10.0%
* episode of diabetic ketoacidosis (DKA) in the past 3 months
* are currently pregnant
* BMI \< 18.5 kg/m2 and pediatric patients with BMI \< 5th percentile DRUG: Liraglutide
Maturity Onset Diabetes of the Young
Food-based Support for Hospitalized Children and Their Families (FRESH)
Kathy Auger - katherine.auger@cchmc.org
ALL
Up to 21 years old
NA
NCT06946355
Inclusion Criteria:
* All families of patients less than 21 years of age with Medicaid insurance or uninsured will be eligible
Exclusion Criteria:
* Patients admitted for end-of-life care, patients who will be discharged to a location other than home, patients who live independently, and patients in county custody. OTHER: In-hospital food support intervention, OTHER: Post-discharge food support intervention
Food Insecurity
Pediatric, Hospitalization, Food Intake
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL (IDEAL2)
cancer@cchmc.org
ALL
7 years to 25 years old
PHASE2
NCT05082519
Inclusion Criteria:
* Patients must be ≥ 7.0 and \<26.0 years of age.
* Patients must have a diagnosis of de novo B-ALL
* Patients must have a M3 marrow (\>25% blasts by morphology) or at least 1,000/µL circulating leukemia cells in PB confirmed by Flow Cytometry (or other convincing evidence of a B-ALL diagnosis not meeting above criteria following central review by the Study Hematopathologist and Study Chair or Vice-Chair).
* The treatment regimen must be the first treatment attempt for B-ALL-
* Must be a multi-agent induction regimen inclusive of vincristine, glucocorticoid, pegaspargase/calaspargase, and daunorubicin or doxorubicin and with a planned duration \<35 days.
* Organ function must meet that required for initiation of chemotherapy
* Patients at diagnosis must meet Karnofsky \> 50% for patients \> 16 years of age and Lansky \> 50% for patients ≤ 16 years of age (or be expected to recover prior to Day 8) .
* If the patient is a female of childbearing potential, a negative urine or serum pregnancy test is required within two weeks prior to enrollment.
Exclusion Criteria:
* Patient will be excluded if they are underweight at time of enrollment (BMI% \<5th percentile for age for patients age 10-19 years, BMI \<18.5 in patients 20-29 years).
* Patients with Down syndrome or a DNA fragility syndrome (such as Fanconi anemia, Bloom syndrome) will be excluded.
* Patient receiving a SJCRH-style "Total Therapy" regimen will be excluded.
* Patients receiving anti-CD20 monoclonal antibody therapy during induction therapy.
* Patients will be excluded if they received treatment for a previous malignancy.
* Patient will be excluded if they are pregnant.
* Patient will be excluded if they have a pre-diagnosis requirement for enteral or parenteral supplementation .
* Patient will be excluded due to inability to perform the intervention (e.g., specific nutritional needs, severe developmental delay, paraplegia)
* Patients will be excluded if they have significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance with the protocol treatment or procedures, interfere with consent, study participation, follow up, or interpretation of study results BEHAVIORAL: IDEAL2 Intervention
B-cell Acute Lymphoblastic Leukemia, Obesity
obesity, leukemia, B-cell leukemia, Pediatric obesity, Pediatric ALL
Effects of Exercise on Lipids and Endothelial Function in Youth
Erin Cain - erin.cain@cchmc.org
ALL
10 years to 20 years old
NA
NCT07409064
Inclusion Criteria:
• Age: 10-20 years
• Obesity as defined by BMI ≥ 30 kg/m2 OR BMI ≥ 95%ile for age and sex
• Planned to start the Healthworks! structured weight loss program.
• English or Spanish speaking -
Exclusion Criteria:
1\. Physician judgement about inability to finish the protocol
\- OTHER: Exercise Program
Obesity & Overweight